SS
TARA icon

Steve Schonfeld’s Protara Therapeutics TARA Stock Holding History

Steve Schonfeld’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-23,955
Closed -$166K – 2528
2021
Q3 		$166K Sell
23,955
-500
-2% -$3.9K ﹤0.01% 1821
2021
Q2 		$238K Buy
24,455
+1,000
+4% +$11.3K ﹤0.01% 1587
2021
Q1 		$371K Buy
+23,455
New +$435K ﹤0.01% 1253

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steve Schonfeld's TARA Position: Q4 2021 in Review

Steve Schonfeld sold out of Protara Therapeutics (TARA) in Q4 2021, closing a stake of 23,955 shares — an estimated $166K sold.

Steve Schonfeld first reported a position in TARA in Q1 2021 and held it in 3 quarters. The position peaked at $371K in Q1 2021. 39 funds tracked by Wall St. Rank hold TARA as of Q4 2021.

  • Steve Schonfeld reported no remaining Protara Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Steve Schonfeld sold 23,955 Protara Therapeutics shares in Q4 2021, an estimated $166K.
  • Steve Schonfeld first reported a position in Protara Therapeutics in Q1 2021 and held it in 3 quarters.
  • Steve Schonfeld's Protara Therapeutics position peaked at $371K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.